17.26
Schlusskurs vom Vortag:
$17.33
Offen:
$17.08
24-Stunden-Volumen:
155.76K
Relative Volume:
0.84
Marktkapitalisierung:
$1.16B
Einnahmen:
$-9,000
Nettoeinkommen (Verlust:
$-68.03M
KGV:
-16.44
EPS:
-1.05
Netto-Cashflow:
$-44.76M
1W Leistung:
-13.14%
1M Leistung:
+18.87%
6M Leistung:
+4.35%
1J Leistung:
+4.48%
Pulse Biosciences Inc Stock (PLSE) Company Profile
Firmenname
Pulse Biosciences Inc
Sektor
Telefon
510-906-4600
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie PLSE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PLSE
Pulse Biosciences Inc
|
17.26 | 1.18B | -9,000 | -68.03M | -44.76M | -1.05 |
![]()
ISRG
Intuitive Surgical Inc
|
436.39 | 156.20B | 9.15B | 2.63B | 1.99B | 7.1661 |
![]()
BDX
Becton Dickinson Co
|
188.36 | 53.50B | 21.39B | 1.61B | 2.55B | 5.5609 |
![]()
RMD
Resmed Inc
|
270.07 | 39.84B | 5.15B | 1.40B | 1.65B | 9.5082 |
![]()
ALC
Alcon Inc
|
74.08 | 35.89B | 10.03B | 1.07B | 1.39B | 2.1549 |
![]()
WST
West Pharmaceutical Services Inc
|
261.17 | 18.87B | 2.96B | 487.70M | 344.00M | 6.6758 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-07 | Eingeleitet | Oppenheimer | Outperform |
2021-07-27 | Eingeleitet | Stephens | Overweight |
2021-03-11 | Eingeleitet | Maxim Group | Buy |
2021-01-26 | Bestätigt | H.C. Wainwright | Buy |
2020-05-12 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2019-02-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten
Using data filters to optimize entry into Pulse Biosciences Inc.July 2025 Trade Ideas & AI Based Buy and Sell Signals - newser.com
Why hedge funds are buying Pulse Biosciences Inc. stockTreasury Yields & AI Powered Market Entry Ideas - newser.com
Is this a good reentry point in Pulse Biosciences Inc.July 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Using fundamentals and technicals on Pulse Biosciences Inc.Portfolio Performance Report & High Return Trade Opportunity Guides - newser.com
Sector ETF performance correlation with Pulse Biosciences Inc.2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
Visualizing Pulse Biosciences Inc. stock with heatmapsBear Alert & Detailed Earnings Play Strategies - newser.com
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse - Yahoo Finance
Tick level data insight on Pulse Biosciences Inc. volatility2025 Buyback Activity & Daily Growth Stock Tips - newser.com
Will Pulse Biosciences Inc. stock beat EPS estimates2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
Pulse Biosciences (PLSE): Assessing Valuation After Recent Share Price Swings - Yahoo Finance
Pulse Biosciences’ Npulse successful in epicardial PFA - BioWorld MedTech
Pulse Biosciences Reveals Positive First-in-Human PFA Data - Medical Product Outsourcing
Is Pulse Biosciences Inc. stock bottoming outJuly 2025 Institutional & Low Risk Entry Point Tips - newser.com
Pulse Biosciences announces presentation of late-breaking data from the nPulse cardiac surgical system - MarketScreener
Pulse Biosciences Announces Results from nPulse Cardiac Surgical System Study - TradingView
Pulse Biosciences reports positive results for cardiac ablation system By Investing.com - Investing.com Nigeria
Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - MarketScreener
Pulse Biosciences reports positive results for cardiac ablation system - Investing.com India
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire
Is now a turning point for Pulse Biosciences Inc.July 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
Pulse Biosciences (NASDAQ:PLSE) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Heatmap analysis for Pulse Biosciences Inc. and competitorsJuly 2025 Trends & Long-Term Capital Growth Strategies - newser.com
Will Pulse Biosciences Inc. continue its uptrendMarket Activity Summary & Real-Time Sentiment Analysis - newser.com
What analysts say about Pulse Biosciences Inc 6L8 stockTrendline Breakouts & Outstanding Investment Portfolio - earlytimes.in
Insider Selling: Pulse Biosciences (NASDAQ:PLSE) Insider Sells 4,600 Shares of Stock - MarketBeat
Pulse Biosciences introduces nPulse Vybrance for nsPFA technology - Traders Union
Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Investing News Network
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire
Pulse Biosciences (NASDAQ:PLSE) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Pulse Biosciences (PLSE) Is Up 11.1% After FDA Clears Cardiac Ablation StudyWhat's Changed - Sahm
Pulse Biosciences (PLSE): Evaluating Its Valuation After Recent Investor Interest - Sahm
Using Ichimoku Cloud for Pulse Biosciences Inc. technicals2025 Dividend Review & Technical Buy Zone Confirmation - newser.com
What does recent volatility data suggest for Pulse Biosciences Inc.Buy Signal & Momentum Based Trading Signals - newser.com
Pulse Biosciences Expands Equity Incentive Plan - MSN
Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial - Insider Monkey
What drives Pulse Biosciences Inc 6L8 stock priceStock Buy Signals & Invest Now – Opportunity Window Closing - earlytimes.in
First Procedures Conducted in PRECISE Benign Thyroid Nodule Study - Medical Product Outsourcing
Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pulse Biosciences Inc-Aktie (PLSE) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):